Bio-Path (NASDAQ:BPTH) Now Covered by Analysts at StockNews.com

Stock analysts at StockNews.com started coverage on shares of Bio-Path (NASDAQ:BPTH) in a note issued to investors on Thursday. The brokerage set a “sell” rating on the stock.

Separately, Roth Mkm reiterated a “buy” rating and set a $20.00 target price on shares of Bio-Path in a research report on Monday, July 8th.

Bio-Path Stock Down 7.5 %

NASDAQ:BPTH opened at $0.98 on Thursday. Bio-Path has a fifty-two week low of $0.85 and a fifty-two week high of $13.90. The firm’s fifty day simple moving average is $1.02 and its 200-day simple moving average is $1.76.

Bio-Path (NASDAQ:BPTH) last issued its earnings results on Thursday, August 15th. The company reported ($1.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.54) by $0.38. During the same quarter in the previous year, the firm earned ($10.60) earnings per share. As a group, analysts forecast that Bio-Path will post -6.2 EPS for the current year.

Hedge Funds Weigh In On Bio-Path

An institutional investor recently bought a new position in Bio-Path stock. Armistice Capital LLC acquired a new position in shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned approximately 4.66% of Bio-Path at the end of the most recent reporting period. 5.74% of the stock is owned by hedge funds and other institutional investors.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.